^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    3d
    BI33 Expect the unexpected. (PubMed, Br J Dermatol)
    After not responding to topical treatments and apremilast, and experiencing short-term remission with phototherapy, he began treatment with methotrexate in consultation with rheumatologists...He was prescribed tamoxifen for the following 5 years...This research is crucial for the development of early detection and prevention strategies. Finally, patients diagnosed with melanoma should continue regular surveillance, not only for potential melanoma recurrence but also to detect new primary cancers.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    tamoxifen • methotrexate
    4d
    Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis (clinicaltrials.gov)
    P2, N=101, Completed, Arcutis Biotherapeutics, Inc. | Recruiting --> Completed | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    5d
    Evaluation the Safety of hemay005 Tablets (clinicaltrials.gov)
    P1, N=468, Completed, Anhui Hemay Pharmaceutical Co., Ltd | Recruiting --> Completed
    Trial completion
    9d
    ALTO-101-201: Study of ALTO-101 in Patients With Schizophrenia (clinicaltrials.gov)
    P2, N=82, Recruiting, Alto Neuroscience | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    10d
    To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment (clinicaltrials.gov)
    P1, N=26, Completed, Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Sep 2025 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    10d
    The Safety and Efficacy of Roflumilast Foam in HS (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    11d
    Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus (clinicaltrials.gov)
    P4, N=64, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed
    Trial completion
    11d
    Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (clinicaltrials.gov)
    P1, N=20, Completed, Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting --> Completed | Trial completion date: May 2025 --> Jan 2025
    Trial completion • Trial completion date
    16d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    18d
    A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 (clinicaltrials.gov)
    P2, N=50, Completed, Chiesi Farmaceutici S.p.A. | Recruiting --> Completed
    Trial completion
    26d
    Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. (PubMed, Diabetes Metab Syndr Obes)
    Roflumilast may offer superior glycemic and oxidative stress control benefits, though neuropathy symptoms control was comparable to ALA. (NCT05369793).
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Daliresp (roflumilast)
    27d
    A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis (clinicaltrials.gov)
    P3, N=51, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed